{"id":"NCT03985943","sponsor":"Galderma R&D","briefTitle":"Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-27","primaryCompletion":"2021-12-29","completion":"2022-08-11","firstPosted":"2019-06-14","resultsPosted":"2024-08-14","lastUpdate":"2024-08-14"},"enrollment":941,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate-to-Severe Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Nemolizumab","otherNames":["CD14152"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Nemolizumab","type":"EXPERIMENTAL"}],"summary":"The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.","primaryOutcome":{"measure":"Percentage of Participants With an Investigator's Global Assessment (IGA) Success (IGA of 0 or 1 and a More Than Equal to [>=] 2-point Reduction): Intent-To-Treat (ITT) Population","timeFrame":"Week 16","effectByArm":[{"arm":"Initial Treatment Period (Baseline - Week 16 Predose): Placebo","deltaMin":24.6,"sd":null},{"arm":"Initial Treatment Period (Baseline - Week 16 Predose): Nemolizumab 30 mg","deltaMin":35.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0003"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":6},"locations":{"siteCount":174,"countries":["United States","Australia","Austria","Canada","Czechia","Germany","Latvia","Lithuania","Netherlands","New Zealand","Poland","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["40360966","40116983","39067461","39008191"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":321},"commonTop":["Dermatitis atopic","Asthma","Headache","COVID-19","Upper respiratory tract infection"]}}